OR WAIT 15 SECS
January 22, 2016.
Shire (Dublin, Ireland) today announced that it has completed its acquisition of Dyax Corp. (Burlington, MA) in an all-cash transaction valued at approximately $5.9 billion, comprised of $37.30 in cash per Dyax share.
Dyax shareholders may receive additional value through a non-tradable contingent value right (CVR) that will pay $4.00 in cash per Dyax share upon approval of DX-2930 for hereditary angioedema (HAE), representing a potential additional $646 million in aggregate contingent consideration.
Shire’s Chief Executive Officer, Flemming Ornskov commented: “The addition of Kalbitor and DX-2930 to our portfolio strengthens our leadership position in HAE and, along with the commercial and research and development expertise at Dyax, is a clear strategic fit for us that advances our position as the global leader in rare diseases."